Valuation: Agios Pharmaceuticals, Inc.

Market Cap 2.54B 2.23B 2.06B 1.9B 3.61B 243B 3.68B 24.76B 9.62B 119B 9.55B 9.34B 414B P/E 2026 *
-6.84x
P/E 2027 * -9.16x
Enterprise Value 2.22B 1.95B 1.8B 1.66B 3.15B 213B 3.22B 21.65B 8.41B 104B 8.35B 8.17B 362B EV / Sales 2026 *
18.5x
EV / Sales 2027 * 9.17x
Free-Float
77.69%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agios Pharmaceuticals, Inc.

1 day-1.38%
1 week+12.59%
Current month+14.01%
1 month+50.36%
3 months+28.52%
6 months+48.93%
Current year+55.44%
1 week 36.77
Extreme 36.77
44.09
1 month 27.7
Extreme 27.7
44.09
Current year 24.29
Extreme 24.29
44.09
1 year 22.24
Extreme 22.24
46
3 years 19.8
Extreme 19.795
62.58
5 years 16.75
Extreme 16.75
62.58
10 years 16.75
Extreme 16.75
99.82
Manager TitleAgeSince
Chief Executive Officer 57 2022-08-07
Director of Finance/CFO 51 2022-09-25
Chief Tech/Sci/R&D Officer 47 2021-08-31
Director TitleAgeSince
Director/Board Member 66 2014-12-08
Director/Board Member 73 2015-06-22
Director/Board Member 73 2017-05-26
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Technology Officer

20,757 0.0349%
06-17Fiscal year

Director

23,509 0.0395%
06-17Fiscal year

Director

23,509 0.0395%
Change 5-day change 1-year change 3-year change Capi.($)
-1.36%+12.59%+8.29%+57.81% 2.54B
-0.38%-3.44%+71.35%+126.62% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.39%+5.79%+22.38%+478.73% 25.26B
-0.41%-4.56%-16.72%-13.34% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+2.99%+40.72%-24.46% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+0.86%+1.84%+29.07%+198.27% 14.1B
Average +0.33%+4.64%+51.16%+140.21% 24.19B
Weighted average by Cap. +1.00%+2.30%+57.91%+141.96%

Financials

2026 *2027 *
Net sales 120M 106M 97.5M 90.1M 171M 11.53B 174M 1.17B 455M 5.64B 452M 442M 19.59B 262M 230M 213M 196M 372M 25.13B 380M 2.55B 993M 12.3B 986M 964M 42.69B
Net income -371M -325M -300M -277M -526M -35.49B -536M -3.61B -1.4B -17.37B -1.39B -1.36B -60.29B -287M -251M -232M -215M -407M -27.45B -415M -2.79B -1.08B -13.43B -1.08B -1.05B -46.63B
Net Debt -319M -280M -258M -239M -452M -30.52B -461M -3.1B -1.21B -14.94B -1.2B -1.17B -51.85B -136M -120M -111M -102M -194M -13.07B -197M -1.33B -516M -6.39B -513M -501M -22.2B
Logo Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. It is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Employees
540
Date Price Change Volume
26-07-09 US$42.31 -1.05% 136,047
26-07-08 US$42.76 -2.84% 1,618,459
26-07-07 US$44.01 +17.71% 2,776,297
26-07-06 US$37.39 -0.51% 476,106
26-07-02 US$37.58 +1.35% 791,174
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
42.76USD
Average target price
42.62USD
Spread / Average Target
-0.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGIO Stock